– Q3 total product revenue of $54.1 million, a YoY increase of 107.5%.– Q3 DAXXIFY® revenue of $22.0 million, and first full year revenue post approval of $71.0 million.– Q3 RHA® Collection revenue of $32.1 million, a YoY increase of 23.2%.– In August, DAXXIFY was approved by the FDA for the treatment of cervical dy.
Record Quarterly Net Revenue of $50 Million for Q3 2023, Up 48% from Q3 2022Raises Full-Year 2023 Net Revenue Guidance from $185 to $195 Million to $194 to $198 MillionOperating Use of Cash in Q3 of $0.9 Million, Demonstrating Continued Progress Towards Achieving Profitability1 with Existing Liquidity“Extra-Strength.
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Record Quarterly Net Revenue of $50 Million for Q3 2023, Up 48% from Q3 2022
Raises Full-Year 2023 Net Revenue Guidance from $185 to $195 Million to $194 to $198 Million
Operating Use of Cash.